Obesity Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Alizyme, Bayer, Bristol-Myers Squibb, Currax Pharmaceuticals, Roche, GSK

The Obesity Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Obesity Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Obesity Market.

Some of the key takeaways from the Obesity Pipeline Report:

• Companies across the globe are diligently working toward developing novel Obesity treatment therapies with a considerable amount of success over the years. 
• Obesity companies working in the treatment market are D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical, Bukwang Pharmaceutical, Caliway Biopharmaceutics, Yuhan, Terns Pharmaceuticals, BioRestorative Therapies, SCOHIA PHARMA, Click Therapeutics, Hanmi Pharmaceuticals, Novo Nordisk, Empros Pharma, Carmot Therapeutics, Eli Lilly and Company, Oral Novo Nordisk, and others, are developing therapies for the Obesity treatment 

• Emerging Obesity therapies in the different phases of clinical trials are- DD03, AX-0601, NPM 139, BK-1701, CBW-520, YH34160, TERN-601, Thermostem, SCO-267, CT-181, HM15136, NNC0480-0389, EMP-16, CT-868, Tirzepatide, Semaglutide, and others are expected to have a significant impact on the Obesity market in the coming years.   
• In June 2023, Comprehensive findings from SURMOUNT-2, a phase 3 clinical trial assessing the effectiveness and safety of Eli Lilly and Company’s tirzepatide (at doses of 10 mg and 15 mg) for managing weight in individuals dealing with obesity or overweight and type 2 diabetes, indicated that tirzepatide resulted in greater weight loss compared to the placebo for both dosage levels. These results were shared at a symposium during the American Diabetes Association’s® (ADA) 83rd Scientific Sessions and were concurrently published in The Lancet.

Obesity Overview

Obesity is acknowledged as a chronic or non-communicable ailment, characterized by a multifaceted and intricate nature, affecting individuals primarily due to excessive adiposity or body fat rather than solely body size. This condition can result in metabolic manifestations beyond physical appearance. The undesirable increase in body weight, contributing to obesity and overweight, stands as a primary factor driving the global surge in non-communicable diseases. Consequently, it is categorized as a non-communicable disease.

Get a Free Sample PDF Report to know more about Obesity Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/obesity-pipeline-insight

Emerging Obesity Drugs Under Different Phases of Clinical Development Include:

• DD03: D&D Pharmatech
• AX-0601: ProQR Therapeutics
• NPM 139: Nano Precision Medical
• BK-1701: Bukwang Pharmaceutical
• CBW-520: Caliway Biopharmaceutics
• YH34160: Yuhan
• TERN-601: Terns Pharmaceuticals
• Thermostem: BioRestorative Therapies
• SCO-267: SCOHIA PHARMA
• CT-181: Click Therapeutics
• HM15136: Hanmi Pharmaceuticals
• NNC0480-0389: Novo Nordisk
• EMP-16: Empros Pharma
• CT-868: Carmot Therapeutics
• Tirzepatide: Eli Lilly and Company
• Semaglutide: Oral Novo Nordisk

Obesity Route of Administration

Obesity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Obesity Molecule Type

Obesity Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Obesity Pipeline Therapeutics Assessment

• Obesity Assessment by Product Type
• Obesity By Stage and Product Type
• Obesity Assessment by Route of Administration
• Obesity By Stage and Route of Administration
• Obesity Assessment by Molecule Type
• Obesity by Stage and Molecule Type

DelveInsight’s Obesity Report covers around 130+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Obesity product details are provided in the report. Download the Obesity pipeline report to learn more about the emerging Obesity therapies

Some of the key companies in the Obesity Therapeutics Market include:

Key companies developing therapies for Obesity are – Alizyme, Bayer AG, Bristol-Myers Squibb, Currax Pharmaceuticals LLC, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Merck & Co. Inc., Norgine BV, Novo Nordisk AS, Pfizer Inc., Rhythm Pharmaceuticals, Takeda Pharmaceuticals, Vivus Inc., Zafgan, Zydus Cadila, and others.

Obesity Pipeline Analysis:

The Obesity pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Obesity with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Obesity Treatment.
• Obesity key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Obesity Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Obesity market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Obesity drugs and therapies

Obesity Pipeline Market Drivers

• Rise in prevalence of Obesity, growing Research and Development Activities to develop novel therapies to treat obesity, changing lifestyle patterns are some of the important factors that are fueling the Obesity Market.

Obesity Pipeline Market Barriers

• However, challenges associated with the discovery of anti-obesity drugs, economic burden associated with obesity and other factors are creating obstacles in the Obesity Market growth.

Scope of Obesity Pipeline Drug Insight    

• Coverage: Global
• Key Obesity Companies: D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical, Bukwang Pharmaceutical, Caliway Biopharmaceutics, Yuhan, Terns Pharmaceuticals, BioRestorative Therapies, SCOHIA PHARMA, Click Therapeutics, Hanmi Pharmaceuticals, Novo Nordisk, Empros Pharma, Carmot Therapeutics, Eli Lilly and Company, Oral Novo Nordisk, and others
• Key Obesity Therapies: DD03, AX-0601, NPM 139, BK-1701, CBW-520, YH34160, TERN-601, Thermostem, SCO-267, CT-181, HM15136, NNC0480-0389, EMP-16, CT-868, Tirzepatide, Semaglutide, and others
• Obesity Therapeutic Assessment: Obesity current marketed and Obesity emerging therapies
• Obesity Market Dynamics: Obesity market drivers and Obesity market barriers 

Request for Sample PDF Report for Obesity Pipeline Assessment and clinical trials

Table of Contents

1. Obesity Report Introduction

2. Obesity Executive Summary

3. Obesity Overview

4. Obesity- Analytical Perspective In-depth Commercial Assessment

5. Obesity Pipeline Therapeutics

6. Obesity Late Stage Products (Phase II/III)

7. Obesity Mid Stage Products (Phase II)

8. Obesity Early Stage Products (Phase I)

9. Obesity Preclinical Stage Products

10. Obesity Therapeutics Assessment

11. Obesity Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Obesity Key Companies

14. Obesity Key Products

15. Obesity Unmet Needs

16 . Obesity Market Drivers and Barriers

17. Obesity Future Perspectives and Conclusion

18. Obesity Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services